[1]
|
万燕萍, 马雄, 王炳元, 等. 非酒精性脂肪性肝病防治指南(2018年更新版) [J]. 临床肝胆杂志, 2018, 34(5): 947-957.
|
[2]
|
Eslam, M., Sarin, S.K., Wong, V.W., et al. (2020) The Asian Pacific Association for the Study of the Liver Clinical Practice Guidelines for the Diagnosis and Management of Metabolic Associated Fatty Liver Disease. Hepatology International, 14, 889-919. https://doi.org/10.1007/s12072-020-10094-2
|
[3]
|
常彬霞, 李保森, 邹正升. 《2016年欧洲肝病学会、欧洲糖尿病学会和欧洲肥胖学会临床实践指南: 非酒精性脂肪性肝病》摘译[J]. 临床肝胆病杂志, 2016, 32(8): 1450-1454.
|
[4]
|
郑海兰, 李凡, 丁维, 等. 中性粒细胞/淋巴细胞比值与2型糖尿病合并非酒精性脂肪肝的相关性分析[J]. 安徽医学, 2020, 41(5): 562-566.
|
[5]
|
Younossi, Z.M., Koenig, A.B., Ab-delatif, D., et al. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Preva-lence, Incidence, and Outcomes. Hepatology, 64, 73-84.
https://doi.org/10.1002/hep.28431
|
[6]
|
Sookoian, S. and Pirola, C.J. (2019) Review Article: Shared Disease Mechanisms between Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome—Translating Knowledge from Sys-tems Biology to the Bedside. Alimentary Pharmacology & Therapeutics, 49, 516-527. https://doi.org/10.1111/apt.15163
|
[7]
|
Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., et al. (2017) Long-Term Nutritional Intake and the Risk for Non-Alcoholic Fatty Liver Disease (NAFLD): A Population Based Study. Journal of Hepatology, 47, 711-717.
https://doi.org/10.1016/j.jhep.2007.06.020
|
[8]
|
刘静, 柳银兰, 杨文君, 等. 高脂高果糖饮食诱导非酒精性脂肪性肝炎小鼠模型的建立和鉴定[J]. 中华肝脏病杂志, 2014, 22(6): 445-450.
|
[9]
|
Ristic-Medic, D., Kovacic, M., Takic, M., et al. (2020) Calorie-Restricted Mediterranean and Low-Fat Diets Affect Fatty Acid Status in Individuals with Nonalcoholic Fatty Liver Disease. Nutrients, 13, Article No. 15.
https://doi.org/10.3390/nu13010015
|
[10]
|
Ma, Y., Yang, W., Simon, T.G., et al. (2019) Dietary Patterns and Risk of Hepatocellular Carcinoma among U.S. Men and Women. Hepatology, 70, 577-586. https://doi.org/10.1002/hep.30362
|
[11]
|
Torres, L.F., Cogliati, B. and Otton, R. (2019) Green Tea Prevents NAFLD by Modulation of miR-34a and miR-194 Expression in a High-Fat Diet Mouse Model. Oxidative Medicine and Cellular Longevity, 2019, Article ID: 4168380.
https://doi.org/10.1155/2019/4168380
|
[12]
|
Yuichiro, E., Yochiro, K., Hideyuki, H., et al. (2015) Pilot Study of Li-raglutide Effects in Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease with Glucose Intolerance in Japanese Patients (LEAN-J). Hepatology Research, 45, 269-278. https://doi.org/10.1111/hepr.12351
|
[13]
|
肖倩倩, 王梦雨, 范建高. 亚太肝病研究学会代谢相关脂肪性肝病临床诊疗指南(治疗部分)简介[J]. 临床肝胆病杂志, 2021, 37(1): 41-45.
|
[14]
|
Golden, S.H., Brown, A., Cauley, J.A., et al. (2012) Health Disparities in Endocrine Disor-ders: Biological, Clinical, and Nonclinical Factors—An Endocrine Society Scientific Statement. The Journal of Clinical Endocrinology & Metabolism, 9, E1579-E1639. https://doi.org/10.1210/jc.2012-2043
|
[15]
|
Park, J.H., Kim, J.Y., Kim, S.H., et al. (2020) A Latent Class Analysis of Dietary Behaviours Associated with Metabolic Syndrome: A Retro-spective Observational Cross-Sectional Study. Nutrition Journal, 19, Article No. 116.
https://doi.org/10.1186/s12937-020-00636-7
|
[16]
|
Miller, E.F. (2020) Nutrition Management Strategies for Nonal-coholic Fatty Liver Disease: Treatment and Prevention. Clinical Liver Disease, 15, 144-148. https://doi.org/10.1002/cld.918
|
[17]
|
Younossi, Z.M. (2019) Non-Alcoholic Fatty Liver Disease—A Global Public Health Perspective. Journal of Hepatology, 70, 531-544. https://doi.org/10.1016/j.jhep.2018.10.033
|
[18]
|
Bifari, F., Manfrini, R., Dei, C.M., et al. (2018) Multiple Target Tissue Effects of GLP-1 Analogues on Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). Pharmacological Research, 137, 219-229.
https://doi.org/10.1016/j.phrs.2018.09.025
|
[19]
|
Ivancovsky-Wajcman, D., Fliss-Isakov, N., Salomone, F., et al. (2019) Dietary Vitamin E and C Intake Is Inversely Associated with the Severity of Nonalcoholic Fatty Liver Disease. Digestive and Liver Disease, 51, 1698-1705.
https://doi.org/10.1016/j.dld.2019.06.005
|
[20]
|
Bril, F., Biernacki, D.M., Kalavalapalli, S., et al. (2019) Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care, 42, 1481-1488.
https://doi.org/10.2337/dc19-0167
|
[21]
|
Vos, M.B., Abrams, S.H., Barlow, S.E., et al. (2017) NASPGHAN Clini-cal Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommenda-tions from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). Journal of Pediatric Gastroenterology and Nutrition, 64, 319-334. https://doi.org/10.1097/MPG.0000000000001482
|
[22]
|
Cusi, K., Orsak, B., Bril, F., et al. (2016) Long-Term Pioglitazone Treatment for Patients with Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Annals of Internal Medicine, 165, 305-315.
https://doi.org/10.7326/M15-1774
|
[23]
|
Majzoub, A.M., Nayfeh, T., Barnard, A., et al. (2021) Systematic Review with Network Meta-Analysis: Comparative Efficacy of Pharmacologic Therapies for Fibrosis Improvement and Resolu-tion of NASH. Alimentary Pharmacology & Therapeutics, 54, 880-889. https://doi.org/10.1111/apt.16583
|
[24]
|
Cheen, A.J. (2018) Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Circulation Research, 122, 1439-1459. https://doi.org/10.1161/CIRCRESAHA.117.311588
|
[25]
|
Smati, S., Canivet, C.M., Boursier, J., et al. (2021) An-ti-Diabetic Drugs and NASH: From Current Options to Promising Perspectives. Expert Opinion on Investigational Drugs, 30, 813-825.
https://doi.org/10.1080/13543784.2021.1951701
|
[26]
|
Rakipovski, G., Rolin, B., Nohr, J., et al. (2018) The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That In-cludes Inflammatory Pathways. JACC: Basic to Translational Science, 3, 844-857. https://doi.org/10.1016/j.jacbts.2018.09.004
|
[27]
|
Matikainen, N., Soderlund, S., Bjornson, E., et al. (2019) Lirag-lutide Treatment Improves Postprandial Lipid Metabolism and Cardiometabolic Risk Factors in Humans with Adequately Controlled Type 2 Diabetes: A Single-Centre Randomized Controlled Study. Diabetes, Obesity and Metabolism, 21, 84-94. https://doi.org/10.1111/dom.13487
|
[28]
|
Cho, K.Y., Nakamura, A., Omori, K., et al. (2021) Favorable Effect of Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Non-Alcoholic Fatty Liver Disease Compared with Pioglitazone. Journal of Diabetes Investigation, 12, 1272-1277. https://doi.org/10.1111/jdi.13457
|
[29]
|
Mantovani, A., Petracca, G., Csermely, A., et al. (2020) Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Metabolites, 11, Article No. 22.
https://doi.org/10.3390/metabo11010022
|
[30]
|
Han, T., Fan, Y., Gao, J., et al. (2021) Sodium Glucose Cotrans-porter 2 Inhibitor Dapagliflozin Depressed Adiposity and Ameliorated Hepatic Steatosis in High-Fat Diet Induced Obese Mice. Adipocyte, 10, 446-455.
https://doi.org/10.1080/21623945.2021.1979277
|
[31]
|
Luo, J., Sun, P., Wang, Y., et al. (2021) Dapagliflozin At-tenuates Steatosis in Livers of High-Fat Diet-Induced Mice and Oleic Acid-Treated L02 Cells via Regulating AMPK/mTOR Pathway. European Journal of Pharmacology, 907, Article ID: 174304. https://doi.org/10.1016/j.ejphar.2021.174304
|
[32]
|
Yuichiro Yshino, T., Mamoru, Y., et al. (2017) Atorvastatin Reduces Cardiac and Adipose Tissue Inflammation in Rats with Metabolic Syndrome. International Journal of Cardiol-ogy, 240, 332-338.
https://doi.org/10.1016/j.ijcard.2017.04.103
|
[33]
|
胥媚, 张铭烜, 张倩, 等. 减重手术与多种健康相关结局: 一项伞状评价[J]. 中国全科医学, 2021, 24(29): 3742-3750.
|
[34]
|
Kwong, A.J., Devuni, D., Wang, C., et al. (2020) Outcomes of Liver Transplantation among Older Recipients with Non-Alcoholic Steatohepatitis in a Large Multicenter U.S. Cohort (REALT). Liver Transplantation, 26, 1492-1503.
https://doi.org/10.1002/lt.25863
|
[35]
|
Alvarez, C.S., Graubard, B.I., Thistle, J.E., et al. (2020) Attributable Fractions of Nonalcoholic Fatty Liver Disease for Mortality in the United States: Results from the Third National Health and Nutri-tion Examination Survey with 27 Years of Follow-Up. Hepatology, 72, 430-440. https://doi.org/10.1002/hep.31040
|
[36]
|
Chalasani, N., Younossi, Z., Lavine, J.E., et al. (2018) The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology, 67, 328-357.
https://doi.org/10.1002/hep.29367
|